Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 267 results found. Search for [ Pfizer COVID-19 vaccine trials india ]

Results 120 to 140 of 267
PB Jayakumar
November 28, 2020
Serum Institute will have a capacity to make over 2.5 billion doses of vaccines a year as it is currently upscaling the capacity from over 1.6 billion doses  


Reuters
November 28, 2020
Vaccines by Pfizer and BioNtech, as well as Moderna and AstraZeneca have shown promising results in large clinical trials, but there is no question of \"cutting corners\", said Thomas Cueni, director-general of the IFPMA


BusinessToday.In
November 27, 2020
After the publication of early data from phase-3 clinical trials, drugmakers Pfizer and BioNTech have sought regulatory approval to deploy their inoculation under emergency-use rules. American biotech company Moderna is also likely to do the same soon


Manoj Sharma
November 27, 2020
New vaccines are rarely certified for efficacy above 90 per cent. Their efficacy improves as millions are vaccinated over decades. In fact, most vaccines get certified in the 40-60 per cent efficacy band


BusinessToday.In
November 27, 2020
The company could be looking at manufacturing 100 million doses to begin with, as per Chairman Pankaj Patel.


Rajeev Dubey
New Delhi, November 25, 2020
In stark contrast to the mayhem around the world, India's top three candidates - Serum-Oxford, Bharat Biotech and Zydus Cadila continued their scientific pursuits unobtrusively (the fourth, DRL-Gamaleya, just started India trials). At least 16 more vaccines are under development at home


PB Jayakumar & Joe C Mathew
New Delhi, November 25, 2020
The world of vaccine and drug development is being reset. Here's how Indian pharma must reinvent to lead the new era of drug discovery and research


PB Jayakumar & Joe C Mathew
New Delhi, November 25, 2020
A blow-by-blow account of how Indian vaccines are being readied


Aseem Thapliyal
November 25, 2020
Sensex climbed 302 points to 44,825 and Nifty gained 90 points to 13,145


Reuters
November 24, 2020
Brent crude rose 51 cents, or 1.1%, to $46.57 a barrel by 1322 GMT and hit a session high of $46.72, its highest since March 6. U.S. West Texas Intermediate crude gained 63 cents, or 1.5%, to $43.69


Joe C Mathew
November 24, 2020
The announcement that comes a day after Oxford-Astrazeneca announced a similar level of efficacy for its COVID-19 vaccine allows India to hope for two vaccines to fight the COVID-19 pandemic in the country


BusinessToday.In
November 24, 2020
Vardhan says it makes no sense to consider Pfizer as pharma major is yet to get approval in the US. After requisite approvals, US pharma major will have to cater to needs of its own country's population first


BusinessToday.In
November 23, 2020
Centre is worried about the caseload surge in urban centres, which has resulted in the enforcement of measures such as curfews by state governments.


BusinessToday.In
November 23, 2020
The panel-led by Dravida Munnetra Kazhagam (DMK) lawmaker Kanimozhi Karunanidhi will hear officials of pharmaceutical departments on the status of the COVID-19 vaccine


BusinessToday.In
November 23, 2020
The Prime Minister is expected to hold two back-to-back meetings, one with those states with high caseloads and another related to vaccine distribution strategy.


BusinessToday.In
November 22, 2020
Bharat Biotech has started the phase- 3 trial of its potential COVID-19 vaccine, involving 26,000 volunteers this month across 25 centres in the country, including Hyderabad, Goa, Nagpur, Bhubaneswar, and Aligarh


BusinessToday.In
November 21, 2020
The participant was admitted to a hospital with viral pneumonitis, few days after being given the vaccine. He was discharged after a week.


Joe C Mathew
November 21, 2020
\"We expect emergency authorisation for Oxford-Astrazeneca vaccine to be sought in the UK. If so, it will give an opportunity for India regulator also (to consider such an option),\" says Dr Vinod Paul, chairman of the National Expert Group on Vaccine Administration for COVID-19


BusinessToday.In
November 21, 2020
Bharat Biotech, the developer of India's indigenous vaccine Covaxin, has said that it is planning to enrol about 2,000 participants each in metros for Phase-3 trials of its COVID-19 vaccine that began earlier this week


BusinessToday.In
November 21, 2020
Pfizer that its EUA submission is supported by solicited safety data from a randomised subset of approximately 8,000 participants aged 18 years or above and unsolicited safety data from approximately 38,000 trial participants


PAGES 7 OF 14  678910